Feasibility Study of the Assessment of Symptom-Related Cytokines in NSCLC Patients Undergoing Chemoradiation Therapy
Principal Investigator: Xin Shelley Wang, M.D., M.P.H.
The clinical experiences and literature on physical symptoms and psychosocial adjustment related to radiotherapy indicates that many patients experience multiple physical, affective and cognitive symptoms during the period of therapy. The documentation of symptoms by multiple symptom assessment tools in the research is particularly impressive in that the assessment tools in these studies typically did not include a thorough assessment of symptoms.
There is little study focus on the mechanisms of multiple symptoms for this specific sample, such as a study of changes in a panel of cytokines during therapy. This study will provide a comprehensive assessment of the frequency and severity of multiple symptoms that patients experience, and to examine the potential interrelationships of symptoms and cytokines.
- To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (Interleukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha (TNF) and symptoms and cognitive impairment related to chemoradition therapy (pre, during and one month post therapy) among patients with non-small cell lung cancer (NSCLC)
- To determine the feasibility of studying neurocognitive function in patients with NSCLC at presentation and during chemoradition therapy to determine the prevalence, severity and pattern of cognitive symptoms
In this longitudinal study we will follow patients with NSCLC undergoing chemoradiation and assess them before treatment begins, weekly during treatment and one month after treatment ends. Assessment will include neurocognitive testing, lab draws and symptom assessment.
- Cognitive measures
- Laboratory draws for cytokine data
- MD Anderson Symptom Inventory – Lung (MDASI-Lung)
For more information
Contact Xin Shelley Wang, M.D., M.P.H., at email@example.com